Difference between revisions of "Fludarabine (Fludara)"
m |
m |
||
| Line 5: | Line 5: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
==Patient drug information== | ==Patient drug information== | ||
| Line 36: | Line 26: | ||
[[Category:Purine analogues]] | [[Category:Purine analogues]] | ||
[[Category:Acute myeloid leukemia medications]] | [[Category:Acute myeloid leukemia medications]] | ||
| + | [[Category:Aggressive Non-Hodgkin lymphoma medications]] | ||
[[Category:Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications]] | [[Category:Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications]] | ||
[[Category:Follicular lymphoma medications]] | [[Category:Follicular lymphoma medications]] | ||
| + | [[Category:Mantle cell lymphoma medications]] | ||
[[Category:Marginal zone lymphoma medications]] | [[Category:Marginal zone lymphoma medications]] | ||
[[Category:Transplant medications]] | [[Category:Transplant medications]] | ||
| + | [[Category:Waldenström macroglobulinemia medications]] | ||
Revision as of 17:33, 11 June 2014
General information
Class/mechanism: Purine analog, antimetabolite; fludarabine is converted to the active compound, 2-fluoro-ara-ATP, which inhibits DNA synthesis by inhibiting DNA polymerase alpha, ribonucleotide reductase, and DNA primase. Relatively resistant to deamination by adenosine deaminase. The mechanism of action is not completely characterized and may be multi-faceted.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Fludarabine (Fludara) patient drug information (Chemocare)[3]
- Fludarabine (Fludara) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 4/18/1991: Initial FDA approval
Also known as
Beneflur, FAMP, Fludarabine Phosphate, Fludara Lyophilisat, Oforta, Trav Fludarabine.
References
- Drug index
- Chemotherapy
- DNA synthesis inhibitors
- Nucleic acid analogs
- Antimetabolites
- Purine analogues
- Acute myeloid leukemia medications
- Aggressive Non-Hodgkin lymphoma medications
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications
- Follicular lymphoma medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Transplant medications
- Waldenström macroglobulinemia medications